

## **CHAPTER 23-23.1 LAETRILE**

### **23-23.1-01. Use of laetrile authorized.**

No hospital or health facility may interfere with the physician-patient relationship by restricting or forbidding the use of amygdalin when prescribed or administered by a licensed physician and requested by a patient unless the substance as prescribed or administered by the physician is found to be harmful by the North Dakota board of medicine in a hearing conducted pursuant to chapter 28-32.

### **23-23.1-02. Disciplinary action for administering or prescribing laetrile subject to finding of harmfulness.**

No physician may be subject to disciplinary action by the North Dakota board of medicine for prescribing or administering amygdalin to a patient under the physician's care who has requested the substance unless the board, in a hearing conducted pursuant to chapter 28-32, has made a formal finding that the substance is harmful.

### **23-23.1-03. Hearing of board on effects of laetrile - Rules.**

Any person may petition, or the board on its own motion may convene, a public hearing to determine the effects of the use of amygdalin and to promulgate rules and regulations pursuant to chapter 28-32 as to its use and administration.